NasdaqGS:TECH - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
6/30/2026	1,380	271	340	400	11
6/30/2025	1,248	228	334	391	13
6/30/2024	1,159	180	243	302	14
3/31/2024	1,154	203	251	307	N/A
12/31/2023	1,145	224	225	276	N/A
9/30/2023	1,144	247	215	258	N/A
6/30/2023	1,137	285	216	254	N/A
3/31/2023	1,124	271	233	274	N/A
12/31/2022	1,120	262	252	296	N/A
9/30/2022	1,118	292	285	333	N/A
6/30/2022	1,106	272	280	325	N/A
3/31/2022	1,076	225	302	345	N/A
12/31/2021	1,030	210	308	346	N/A
9/30/2021	985	177	295	335	N/A
6/30/2021	931	140	308	352	N/A
3/31/2021	848	184	225	275	N/A
12/31/2020	799	175	201	250	N/A
9/30/2020	760	248	179	231	N/A
6/30/2020	739	229	153	205	N/A
3/31/2020	755	187	170	216	N/A
12/31/2019	745	195	165	207	N/A
9/30/2019	734	93	151	183	N/A
6/30/2019	714	96	156	182	N/A
3/31/2019	703	121	171	191	N/A
12/31/2018	682	96	154	173	N/A
9/30/2018	661	128	145	165	N/A
6/30/2018	643	126	149	170	N/A
3/31/2018	619	112	135	156	N/A
12/31/2017	599	114	N/A	160	N/A
9/30/2017	577	73	N/A	162	N/A
6/30/2017	563	76	N/A	144	N/A
3/31/2017	541	74	N/A	129	N/A
12/31/2016	528	82	N/A	141	N/A
9/30/2016	517	101	N/A	138	N/A
6/30/2016	499	104	N/A	144	N/A
3/31/2016	482	105	N/A	145	N/A
12/31/2015	465	99	N/A	138	N/A
9/30/2015	456	107	N/A	135	N/A
6/30/2015	452	108	N/A	139	N/A
3/31/2015	427	108	N/A	140	N/A
12/31/2014	408	116	N/A	144	N/A
9/30/2014	380	107	N/A	140	N/A
6/30/2014	358	111	N/A	137	N/A
3/31/2014	345	113	N/A	129	N/A
12/31/2013	330	114	N/A	127	N/A
9/30/2013	321	114	N/A	127	N/A
6/30/2013	311	113	N/A	124	N/A

アナリストによる今後の成長予測

収入対貯蓄率: TECHの予測収益成長率 (年間16.2% ) は貯蓄率 ( 2.4% ) を上回っています。

収益対市場: TECHの収益 ( 16.2% ) はUS市場 ( 14.8% ) よりも速いペースで成長すると予測されています。

高成長収益: TECHの収益は増加すると予測されていますが、大幅には増加しません。

収益対市場: TECHの収益 ( 8.4% ) US市場 ( 8.7% ) よりも低い成長が予測されています。

高い収益成長: TECHの収益 ( 8.4% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: TECHの自己資本利益率は、3年後には低くなると予測されています ( 14 %)。

Bio-Techne 将来の成長

Future 基準チェック /26

主要情報

今後の成長に関する最新情報

Consensus EPS estimates fall by 17%

Price target decreased by 19% to US$81.33

Consensus EPS estimates fall by 17%

Price target decreased to US$423

Recent updates

When Should You Buy Bio-Techne Corporation (NASDAQ:TECH)?

Bio-Techne Corporation to Showcase Multiple Applications of the MauriceFlex™? System at the Annual ASMS Conference

Bio-Techne Corporation and Regulus Therapeutics Inc. Announces Continued Technical and Clinical Collaboration

Bio-Techne Corporation's (NASDAQ:TECH) Shares Climb 33% But Its Business Is Yet to Catch Up

Third quarter dividend of US$0.08 announced

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Bio-Techne Corporation Declares Dividend for the Quarter Ended March 31, 2024, Payable on May 24, 2024

Bio-Techne Corporation Appoints Dr. Judith Klimovsky to Board of Directors

These 4 Measures Indicate That Bio-Techne (NASDAQ:TECH) Is Using Debt Reasonably Well

Bio-Techne Corporation and Novomol-Dx Announce Point-of-Care Ocular Biomarker Assay

Bio-Techne Corporation (NASDAQ:TECH) Shares Could Be 32% Above Their Intrinsic Value Estimate

Bio-Techne: Secular Growth Opportunities Always Exhibit Financial Excellence

Independent Director recently sold US$801k worth of stock

Consensus EPS estimates fall by 17%

Second quarter dividend of US$0.08 announced

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Bio-Techne Corporation Announces to Pay A Dividend for the Quarter Ended December 31, 2023, Payable February 26, 2024

Bio-Techne Corporation Sets New Standard with the Development of A Next-Generation, Protease-Free RNAscope Spatial Multiomics Workflow

Bio-Techne Corporation to Report Q2, 2024 Results on Feb 01, 2024

We Think Bio-Techne (NASDAQ:TECH) Can Stay On Top Of Its Debt

Bio-Techne Corporation Appoints Matthew F. Mcmanus as President, Diagnostics and Genomics Segment, Effective January 8, 2024

Bio-Techne Corporation (NASDAQ:TECH) Investors Are Less Pessimistic Than Expected

Executive VP of Finance & CFO exercised options and sold US$1.5m worth of stock

Estimating The Intrinsic Value Of Bio-Techne Corporation (NASDAQ:TECH)

New minor risk - Earnings quality

Price target decreased by 19% to US$81.33

Bio-Techne Corporation Announces to Pay A Dividend for the Quarter Ended September 30, 2023, Will Be Payable November 24, 2023

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Bio-Techne Corporation to Present New Data Using Lunaphore's Comet Technology at the Society for Immunotherapy of Cancer's 38th Annual Meeting

Bio-Techne Corporation Announces Executive Changes

Is Now An Opportune Moment To Examine Bio-Techne Corporation (NASDAQ:TECH)?

Bio-Techne Corporation Launches the New Maurice Chromeleon Driver Kit, Which Enables Control of its Maurice™ Instrument with the Thermo Scientific™ Chromeleon™ Chromatography Data System

Bio-Techne (NASDAQ:TECH) Has A Rock Solid Balance Sheet

Bio-Techne Corporation, Annual General Meeting, Oct 26, 2023

A Look At The Intrinsic Value Of Bio-Techne Corporation (NASDAQ:TECH)

New minor risk - Earnings quality

Consensus EPS estimates fall by 17%

Full year 2023 earnings: EPS exceeds analyst expectations

Bio-Techne Corporation (NasdaqGS:TECH) acquired Lunaphore Technologies SA from PHC Holdings Corporation (TSE:6523) and others.

At US$80.80, Is Bio-Techne Corporation (NASDAQ:TECH) Worth Looking At Closely?

Bio-Techne Corporation (NasdaqGS:TECH) reached an agreement to acquire Lunaphore Technologies SA.

Does Bio-Techne (NASDAQ:TECH) Have A Healthy Balance Sheet?

With EPS Growth And More, Bio-Techne (NASDAQ:TECH) Makes An Interesting Case

Bio-Techne Corporation's (NASDAQ:TECH) Intrinsic Value Is Potentially 25% Below Its Share Price

Bio-Techne Corporation Announces Launch of Kappa and Lambda Rnascope Ish Probes as Analyte Specific Reagents (Asrs) for the Detection of Immunoglobulin Kappa and Lambda Light Chains mRNA

Bio-Techne Declares Quarterly Dividend, Payable May 26, 2023

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

When Should You Buy Bio-Techne Corporation (NASDAQ:TECH)?

Bio-Techne (NASDAQ:TECH) Has A Rock Solid Balance Sheet

Here's Why We Think Bio-Techne (NASDAQ:TECH) Is Well Worth Watching

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Bio-Techne Corporation Declares Dividend for the Quarter Ended December 31, 2022, Payable on February 27, 2023

Bio-Techne Corporation Announces Executive Changes, Effective March 3, 2023

Bio-Techne Launches the Mauriceflex™ System, Adding Cief Fractionation Capability to the Gold Standard Maurice Assays

Bio-Techne Corporation Launches RNAscope Plus Assay to Advance Gene Therapy Development

When Should You Buy Bio-Techne Corporation (NASDAQ:TECH)?

We Think Bio-Techne (NASDAQ:TECH) Can Manage Its Debt With Ease

Bio-Techne Releases MitoBrilliant Fluorescent Dyes, Providing A Next-Generation Tool for Imaging Mitochondria in Live and Fixed Cells

Should You Be Adding Bio-Techne (NASDAQ:TECH) To Your Watchlist Today?

Estimating The Intrinsic Value Of Bio-Techne Corporation (NASDAQ:TECH)

Insufficient new directors

Price target decreased to US$423

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Bio-Techne Corporation Declares Dividend for the Quarter Ended September 30, 2022, Payable on November 28, 2022

Bio-Techne Corporation Announces the Introduction of 3 Novel TSA Vivid Fluorophores for Highly Sensitive Fluorescent Detection of RNAs and Proteins in Cells and Tissues

Bio-Techne Corporation and PROGEN Introduce New Simple Plex AAV Viral Titer Assays

Bio-Techne releases new AVV viral titer assays

Bio-Techne Corporation Commercializes Automated Multi-Omic Rnascope Assays for Spatial Visualization of RNA and Protein Biomarkers in FFPE Tissues

At US$291, Is Bio-Techne Corporation (NASDAQ:TECH) Worth Looking At Closely?

Now 22% undervalued after recent price drop

Does Bio-Techne (NASDAQ:TECH) Have A Healthy Balance Sheet?